greeksoup/ stock research
Stock research / United States / KRYS / FY2021

Krystal Biotech (KRYS) FY2021 results: revenue $0

Krystal Biotech, Inc. (KRYS) reported revenue of $0 for fiscal 2021, the year ended 31 December 2021. Net income was -$70 million, and diluted earnings per share $-3.13. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2024.

Revenue
$0
FY2021FY2021
Operating margin
n/a
FY2021FY2021
Net income
-$70 million
FY2021FY2021
Diluted EPS
-$3.13
FY2021FY2021

this yearthe year beforeHover a bar for its figure.

The year in brief

Income statement (profit and loss)

$ millionFY2021Last 8 years
Revenue0.0
Research and development27.9
Operating income-68.3
Interest expense1.5
Pre-tax income-69.6
Income tax0.0
Net income-69.6
Diluted EPS-$3.13
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionFY2021Last 8 years
Operating cash flow-47.9
Capital expenditure68.3
Free cash flow-116
Cash from investing-227
Cash from financing348
Depreciation and amortisation2.8
Share-based compensation15.3
Diluted shares, weighted22m
Shares outstanding at period end25m

Balance sheet

$ millionFY2021Last 8 years
Shareholders' equity594
Debt0.0
Operating lease liabilities7.0
Other liabilities25.7
Total liabilities and equity626
Fixed assets112
Investments161
Cash and equivalents341
Other assets11.5
Total assets626

10-K for the year ended 31 December 2021, filed 26 February 2024: the filing.